Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
DMAC vs ARCT: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
DMAC Captures Overall Composite Edge (46.3 HOLD vs 57.7 HOLD), While ARCT Leads 3–2 on Growth & Valuation Pillars
DMAC Overall Winner
6-Pillar Tally: DMAC 2 – 3 ARCT (1 Tie)
Matrix Metrics: DMAC 5 – 5 ARCT
As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) captures the overall head-to-head institutional edge over Arcturus Therapeutics Holdings Inc. (ARCT) on higher Unified Composite conviction (46.3/100 HOLD vs. 57.7/100 HOLD) after splitting the core matrix 5–5 (led by Profitability & Quality, Options & Positioning), while ARCT wins 3–2 across the 6-pillar growth and valuation breakdown. DMAC trades at $8.39 (N/M Forward P/E, 0.0% operating margin) versus ARCT at $8.43 (2.5x Forward P/E, -311.2% operating margin).
- Composite vs. Pillar Nuance: While ARCT currently prints a higher short-term Unified Composite Score (57.7/100 HOLD vs. DMAC 46.3/100 HOLD), DMAC captures the overall institutional head-to-head verdict (5–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -311.2% operating margin) and revenue trajectory (+0.0% vs. +6.7% YoY).
- Technical & Structure Timing Caution: DMAC trades in a Neutral technical trend (SURGE options phase, RSI 44.7); meanwhile ARCT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About DMAC vs ARCT
DMAC
Head-to-Head Winner
DiaMedica Therapeutics Inc. Common Stock
$8.39
-4.55% 1D
Market Cap
$503.1M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
1.72β · 97% Vol
Unified Composite Score
46.3
HOLD
Tech 30.0
Fund 51.0
Flow 65.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
ARCT
Arcturus Therapeutics Holdings Inc. Common Stock
$8.43
+0.84% 1D
Market Cap
$241.0M
TTM Revenue
$31M
Forward P/E
2.5x
Beta / 30D Vol
2.01β · 127% Vol
Unified Composite Score
57.7
HOLD
Tech 60.0
Fund 62.0
Flow 72.0
Mom 60.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (DMAC 2 – 3 ARCT)
1. Valuation Multiples
ARCT
Forward P/E
N/M
2.5x
Trailing P/E
N/M
2.5x
PEG Ratio
N/M
N/M
EV / Revenue
N/M
2.6x
2. Growth & Scale
ARCT
Revenue Growth (YoY)
+0.0%
+6.7%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
N/A
$31M
Market Cap
$503.1M
$241.0M
3. Profitability & Quality
DMAC
Gross Margin
N/A
N/A
Operating Margin
0.0%
-311.2%
Net Profit Margin
0.0%
-285.9%
Return on Equity (ROE)
-114.6%
-44.4%
4. Balance Sheet & Cash Flow
ARCT
Cash Generation (TTM)
-$32M
-$62M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$4.9M Net Cash
$163M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
DMAC
Options Structure Phase
SURGE
BREAKDOWN
Current IV / %ile
106.3% (14th %ile)
96.3% (7th %ile)
Put/Call OI Skew
N/A
0.07x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Neutral
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: DMAC (5) vs ARCT (5)| Institutional Metric | DMAC | ARCT | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $503.1M | $241.0M | DMAC | |
| Trailing P/E Ratio | N/M | 2.5x | ARCT | |
| Forward P/E Ratio | N/M | 2.5x | ARCT | |
| Revenue Growth (YoY) | +0.0% | +6.7% | ARCT | |
| Operating Margin (TTM) | 0.0% | -311.2% | DMAC | |
| Net Profit Margin | 0.0% | -285.9% | DMAC | |
| Return on Equity (ROE) | -114.6% | -44.4% | ARCT | |
| 52-Week Range Position | 55% ($5–$11) | 24% ($6–$18) | DMAC | |
| Beta / 30D Volatility | 1.72β · 97% Vol | 2.01β · 127% Vol | DMAC | |
| Unified Institutional Score | 46.3 / 100 (HOLD) | 57.7 / 100 (HOLD) | ARCT | |
| Trailing 12M Revenue (USD) | N/A | $31M | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | N/M PEG · 2.6x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$32M ($4.9M Net Cash) | -$62M ($163M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
DMAC +29.3 pp
3M Horizon
DMAC +24.25 pp
6M Horizon
DMAC +27.8 pp
1Y Horizon
DMAC +46.31 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | DMAC Revenue | ARCT Revenue | DMAC Op. Margin | ARCT Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2018 | $0M | $20M | -1352.2% | -138.5% | ARCT |
| FY2019 | N/A | $20M | N/A | -122.7% | ARCT |
| FY2020 | N/A | $10M | N/A | -749.8% | ARCT |
| FY2021 | N/A | $10M | N/A | -1641.3% | ARCT |
| FY2022 | N/A | $210M | N/A | 5.9% | ARCT |
| FY2023 | N/A | $170M | N/A | -46.9% | ARCT |
| FY2024 | N/A | $150M | N/A | -62.8% | ARCT |
| FY2025 | N/A | $80M | N/A | -93.0% | ARCT |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
DMAC
SURGE
Current IV
106.3%
IV Percentile
14th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact DMAC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
ARCT
BREAKDOWN
Current IV
96.3%
IV Percentile
7th %ile
Put/Call OI Skew
0.07x (Call-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact ARCT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
DMAC Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
ARCT Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ DMAC vs ARCT Key Questions & Quantitative Answers
As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) captures the overall head-to-head institutional edge over Arcturus Therapeutics Holdings Inc. (ARCT) on higher Unified Composite conviction (46.3/100 HOLD vs. 57.7/100 HOLD) after splitting the core matrix 5–5 (led by Profitability & Quality, Options & Positioning), while ARCT wins 3–2 across the 6-pillar growth and valuation breakdown. DMAC trades at $8.39 (N/M Forward P/E, 0.0% operating margin) versus ARCT at $8.43 (2.5x Forward P/E, -311.2% operating margin). Composite vs. Pillar Nuance: While ARCT currently prints a higher short-term Unified Composite Score (57.7/100 HOLD vs. DMAC 46.3/100 HOLD), DMAC captures the overall institutional head-to-head verdict (5–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -311.2% operating margin) and revenue trajectory (+0.0% vs. +6.7% YoY). Technical & Structure Timing Caution: DMAC trades in a Neutral technical trend (SURGE options phase, RSI 44.7); meanwhile ARCT is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 39.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
ARCT leads the Growth & Scale pillar: DMAC posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with ARCT at +6.7% YoY revenue growth and +0.0% YoY earnings growth on $31M TTM revenue (N/A gross margin, -311.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), DMAC cumulative revenue shifted N/A while ARCT shifted +300.0%. In operating R&D and SG&A reinvestment, DMAC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ARCT.
ARCT screens cheaper on headline valuation multiples. DMAC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas ARCT trades at 2.5x Forward P/E, 2.5x Trailing P/E, N/M PEG, and 2.6x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DMAC (-114.6% ROE) versus ARCT (-44.4% ROE) capital efficiency.
In options market volatility and institutional positioning, DMAC carries 106.3% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.72β · 97% Vol realized risk). By comparison, ARCT carries 96.3% implied volatility (7th %ile, Compressed (<25th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.01β · 127% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
ARCT vs DMAC · Reverse Pair
DMAC vs TRVI
· Sector Peer
DMAC vs VRCA
· Sector Peer
DMAC vs FENC
· Sector Peer
ARCT vs TWST
· Sector Peer
ARCT vs CDNA
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem